Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas

LESSONS LEARNED. The combination of cisplatin, docetaxel, and erlotinib as frontline treatment for recurrent and/or metastatic head and neck squamous cell carcinomas led to a response rate of 62%. This result exceeded the prespecified target response rate of 50% and represented an improvement compar...

Descripción completa

Detalles Bibliográficos
Autores principales: William, William N., Tsao, Anne S., Feng, Lei, Ginsberg, Lawrence E., Lee, J. Jack, Kies, Merrill S., Glisson, Bonnie S., Kim, Edward S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947451/
https://www.ncbi.nlm.nih.gov/pubmed/29371473
http://dx.doi.org/10.1634/theoncologist.2017-0661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947451/
https://www.ncbi.nlm.nih.gov/pubmed/29371473
http://dx.doi.org/10.1634/theoncologist.2017-0661

Ejemplares similares